FUNDAMENTALS · Fundamentals · US Healthcare

Amneal Pharmaceuticals (AMRX) Fundamentals 2026 — P/E 47.1x, Revenue Analysis | SniperIQ

Amneal Pharmaceuticals (AMRX) is a US-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of $5.7B, trading at

7.86 on the NASDAQ. This SniperIQ fundamentals page covers Amneal Pharmaceuticals's valuation (P/E 47.1x), profitability (net margin 4.0%), revenue (
.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$5.7B
P/E (TTM)47.1x
Net Margin4.0%
Revenue (FY25)
.0B

Full research coverage

Frequently Asked Questions

What is Amneal Pharmaceuticals's market cap?

Amneal Pharmaceuticals (AMRX) has a market capitalization of approximately $5.7B, trading at

7.86 on the NASDAQ. Market cap moves with the live share price.

What is Amneal Pharmaceuticals's P/E ratio?

Amneal Pharmaceuticals's trailing twelve-month P/E ratio is 47.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Amneal Pharmaceuticals?

Amneal Pharmaceuticals runs a net profit margin of 4.0%, a gross margin of 38.7%, and an operating margin of 11.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Amneal Pharmaceuticals generate?

Amneal Pharmaceuticals reported revenue of

.0B for fiscal year 2025, with net income of $72M and earnings per share (EPS) of 0.23. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Amneal Pharmaceuticals pay a dividend?

Amneal Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Amneal Pharmaceuticals financially healthy?

Amneal Pharmaceuticals carries a debt-to-equity ratio of -59.38x and a current ratio of 2.47x, with a market beta of 1.26. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Amneal Pharmaceuticals a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Amneal Pharmaceuticals (AMRX) the key facts are: market cap $5.7B, P/E 47.1x, revenue

.0B, 52-week range 7.665-18.39. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Amneal Pharmaceuticals's full fundamentals live

Get Amneal Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.